"Global Antisense & RNAi Therapeutics Market Overview:
Global Antisense & RNAi Therapeutics Market is expected to grow at a significant rate during the forecast period 2025-2032, with 2024 as the base year.
Global Antisense & RNAi Therapeutics Market Report 2025 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2025-2032.This research study of Antisense & RNAi Therapeutics involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Antisense & RNAi Therapeutics Market:
The Antisense & RNAi Therapeutics Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for Antisense & RNAi Therapeutics Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Antisense & RNAi Therapeutics Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, Antisense & RNAi Therapeutics market has been segmented into:
RNA Interference and Antisense RNA
By Application, Antisense & RNAi Therapeutics market has been segmented into:
Genetic Disease
Cancer
Infectious Disease
Neurodegenerative Disorders
Cardio Metabolic & Renal Disorders
Ocular Disorders
Respiratory Disorders
Skin Disorders and Others
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Antisense & RNAi Therapeutics market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Antisense & RNAi Therapeutics market.
Top Key Players Covered in Antisense & RNAi Therapeutics market are:
Benitec Biopharma Inc.
Silence Therapeutics
Ionis Pharmaceuticalsinc.
Bio-Path Holdings Inc.
Percheron Therapeutics Limited
GSK plc
Olix Pharmaceuticalsinc.
Sanofi
Alnylam Pharmaceuticalsinc. and Arbutus Biopharma
"
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Antisense & RNAi Therapeutics Market by Type
4.1 Antisense & RNAi Therapeutics Market Snapshot and Growth Engine
4.2 Antisense & RNAi Therapeutics Market Overview
4.3 RNA Interference and Antisense RNA
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 RNA Interference and Antisense RNA: Geographic Segmentation Analysis
Chapter 5: Antisense & RNAi Therapeutics Market by Application
5.1 Antisense & RNAi Therapeutics Market Snapshot and Growth Engine
5.2 Antisense & RNAi Therapeutics Market Overview
5.3 Genetic Disease
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Genetic Disease: Geographic Segmentation Analysis
5.4 Cancer
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Cancer: Geographic Segmentation Analysis
5.5 Infectious Disease
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Infectious Disease: Geographic Segmentation Analysis
5.6 Neurodegenerative Disorders
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.6.3 Key Market Trends, Growth Factors and Opportunities
5.6.4 Neurodegenerative Disorders: Geographic Segmentation Analysis
5.7 Cardio Metabolic & Renal Disorders
5.7.1 Introduction and Market Overview
5.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.7.3 Key Market Trends, Growth Factors and Opportunities
5.7.4 Cardio Metabolic & Renal Disorders: Geographic Segmentation Analysis
5.8 Ocular Disorders
5.8.1 Introduction and Market Overview
5.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.8.3 Key Market Trends, Growth Factors and Opportunities
5.8.4 Ocular Disorders: Geographic Segmentation Analysis
5.9 Respiratory Disorders
5.9.1 Introduction and Market Overview
5.9.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.9.3 Key Market Trends, Growth Factors and Opportunities
5.9.4 Respiratory Disorders: Geographic Segmentation Analysis
5.10 Skin Disorders and Others
5.10.1 Introduction and Market Overview
5.10.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.10.3 Key Market Trends, Growth Factors and Opportunities
5.10.4 Skin Disorders and Others: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Antisense & RNAi Therapeutics Market Share by Manufacturer (2023)
6.1.3 Industry BCG Matrix
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 BENITEC BIOPHARMA INC.
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Role of the Company in the Market
6.2.5 Sustainability and Social Responsibility
6.2.6 Operating Business Segments
6.2.7 Product Portfolio
6.2.8 Business Performance
6.2.9 Key Strategic Moves and Recent Developments
6.2.10 SWOT Analysis
6.3 SILENCE THERAPEUTICS
6.4 IONIS PHARMACEUTICALSINC.
6.5 BIO-PATH HOLDINGS INC.
6.6 PERCHERON THERAPEUTICS LIMITED
6.7 GSK PLC
6.8 OLIX PHARMACEUTICALSINC.
6.9 SANOFI
6.10 ALNYLAM PHARMACEUTICALSINC. AND ARBUTUS BIOPHARMA
Chapter 7: Global Antisense & RNAi Therapeutics Market By Region
7.1 Overview
7.2. North America Antisense & RNAi Therapeutics Market
7.2.1 Key Market Trends, Growth Factors and Opportunities
7.2.2 Top Key Companies
7.2.3 Historic and Forecasted Market Size by Segments
7.2.4 Historic and Forecasted Market Size By Type
7.2.4.1 RNA Interference and Antisense RNA
7.2.5 Historic and Forecasted Market Size By Application
7.2.5.1 Genetic Disease
7.2.5.2 Cancer
7.2.5.3 Infectious Disease
7.2.5.4 Neurodegenerative Disorders
7.2.5.5 Cardio Metabolic & Renal Disorders
7.2.5.6 Ocular Disorders
7.2.5.7 Respiratory Disorders
7.2.5.8 Skin Disorders and Others
7.2.6 Historic and Forecast Market Size by Country
7.2.6.1 US
7.2.6.2 Canada
7.2.6.3 Mexico
7.3. Eastern Europe Antisense & RNAi Therapeutics Market
7.3.1 Key Market Trends, Growth Factors and Opportunities
7.3.2 Top Key Companies
7.3.3 Historic and Forecasted Market Size by Segments
7.3.4 Historic and Forecasted Market Size By Type
7.3.4.1 RNA Interference and Antisense RNA
7.3.5 Historic and Forecasted Market Size By Application
7.3.5.1 Genetic Disease
7.3.5.2 Cancer
7.3.5.3 Infectious Disease
7.3.5.4 Neurodegenerative Disorders
7.3.5.5 Cardio Metabolic & Renal Disorders
7.3.5.6 Ocular Disorders
7.3.5.7 Respiratory Disorders
7.3.5.8 Skin Disorders and Others
7.3.6 Historic and Forecast Market Size by Country
7.3.6.1 Bulgaria
7.3.6.2 The Czech Republic
7.3.6.3 Hungary
7.3.6.4 Poland
7.3.6.5 Romania
7.3.6.6 Rest of Eastern Europe
7.4. Western Europe Antisense & RNAi Therapeutics Market
7.4.1 Key Market Trends, Growth Factors and Opportunities
7.4.2 Top Key Companies
7.4.3 Historic and Forecasted Market Size by Segments
7.4.4 Historic and Forecasted Market Size By Type
7.4.4.1 RNA Interference and Antisense RNA
7.4.5 Historic and Forecasted Market Size By Application
7.4.5.1 Genetic Disease
7.4.5.2 Cancer
7.4.5.3 Infectious Disease
7.4.5.4 Neurodegenerative Disorders
7.4.5.5 Cardio Metabolic & Renal Disorders
7.4.5.6 Ocular Disorders
7.4.5.7 Respiratory Disorders
7.4.5.8 Skin Disorders and Others
7.4.6 Historic and Forecast Market Size by Country
7.4.6.1 Germany
7.4.6.2 UK
7.4.6.3 France
7.4.6.4 Netherlands
7.4.6.5 Italy
7.4.6.6 Russia
7.4.6.7 Spain
7.4.6.8 Rest of Western Europe
7.5. Asia Pacific Antisense & RNAi Therapeutics Market
7.5.1 Key Market Trends, Growth Factors and Opportunities
7.5.2 Top Key Companies
7.5.3 Historic and Forecasted Market Size by Segments
7.5.4 Historic and Forecasted Market Size By Type
7.5.4.1 RNA Interference and Antisense RNA
7.5.5 Historic and Forecasted Market Size By Application
7.5.5.1 Genetic Disease
7.5.5.2 Cancer
7.5.5.3 Infectious Disease
7.5.5.4 Neurodegenerative Disorders
7.5.5.5 Cardio Metabolic & Renal Disorders
7.5.5.6 Ocular Disorders
7.5.5.7 Respiratory Disorders
7.5.5.8 Skin Disorders and Others
7.5.6 Historic and Forecast Market Size by Country
7.5.6.1 China
7.5.6.2 India
7.5.6.3 Japan
7.5.6.4 South Korea
7.5.6.5 Malaysia
7.5.6.6 Thailand
7.5.6.7 Vietnam
7.5.6.8 The Philippines
7.5.6.9 Australia
7.5.6.10 New Zealand
7.5.6.11 Rest of APAC
7.6. Middle East & Africa Antisense & RNAi Therapeutics Market
7.6.1 Key Market Trends, Growth Factors and Opportunities
7.6.2 Top Key Companies
7.6.3 Historic and Forecasted Market Size by Segments
7.6.4 Historic and Forecasted Market Size By Type
7.6.4.1 RNA Interference and Antisense RNA
7.6.5 Historic and Forecasted Market Size By Application
7.6.5.1 Genetic Disease
7.6.5.2 Cancer
7.6.5.3 Infectious Disease
7.6.5.4 Neurodegenerative Disorders
7.6.5.5 Cardio Metabolic & Renal Disorders
7.6.5.6 Ocular Disorders
7.6.5.7 Respiratory Disorders
7.6.5.8 Skin Disorders and Others
7.6.6 Historic and Forecast Market Size by Country
7.6.6.1 Turkey
7.6.6.2 Bahrain
7.6.6.3 Kuwait
7.6.6.4 Saudi Arabia
7.6.6.5 Qatar
7.6.6.6 UAE
7.6.6.7 Israel
7.6.6.8 South Africa
7.7. South America Antisense & RNAi Therapeutics Market
7.7.1 Key Market Trends, Growth Factors and Opportunities
7.7.2 Top Key Companies
7.7.3 Historic and Forecasted Market Size by Segments
7.7.4 Historic and Forecasted Market Size By Type
7.7.4.1 RNA Interference and Antisense RNA
7.7.5 Historic and Forecasted Market Size By Application
7.7.5.1 Genetic Disease
7.7.5.2 Cancer
7.7.5.3 Infectious Disease
7.7.5.4 Neurodegenerative Disorders
7.7.5.5 Cardio Metabolic & Renal Disorders
7.7.5.6 Ocular Disorders
7.7.5.7 Respiratory Disorders
7.7.5.8 Skin Disorders and Others
7.7.6 Historic and Forecast Market Size by Country
7.7.6.1 Brazil
7.7.6.2 Argentina
7.7.6.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
Antisense & RNAi Therapeutics Scope:
|
Report Data
|
Antisense & RNAi Therapeutics Market
|
|
Antisense & RNAi Therapeutics Market Size in 2025
|
USD XX million
|
|
Antisense & RNAi Therapeutics CAGR 2025 - 2032
|
XX%
|
|
Antisense & RNAi Therapeutics Base Year
|
2024
|
|
Antisense & RNAi Therapeutics Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Benitec Biopharma Inc., Silence Therapeutics, Ionis Pharmaceuticalsinc., Bio-Path Holdings Inc., Percheron Therapeutics Limited, GSK plc, Olix Pharmaceuticalsinc., Sanofi, Alnylam Pharmaceuticalsinc. and Arbutus Biopharma.
|
|
Key Segments
|
By Type
RNA Interference and Antisense RNA
By Applications
Genetic Disease
Cancer
Infectious Disease
Neurodegenerative Disorders
Cardio Metabolic & Renal Disorders
Ocular Disorders
Respiratory Disorders
Skin Disorders and Others
|
